About Transmembrane channel-like protein 5
Transmembrane channel-like protein 5 (TMC5) is a protein
from Homo sapiens identified by UniProt accession
Q6UXY8, 1006 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | Transmembrane channel-like protein 5 |
|---|
| UniProt accession | Q6UXY8 |
|---|
| Gene | TMC5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1006 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (109)
Diseases linked to this target (Open Targets).
- azoospermia · score 0.09
- cancer · score 0.08
- Male infertility with spermatogenesis disorder due to single gene mutation · score 0.07
- Female infertility due to fertilization defect · score 0.07
- Rare genetic female infertility · score 0.07
- partial chromosome Y deletion · score 0.07
- male infertility with teratozoospermia due to single gene mutation · score 0.07
- chickenpox · score 0.06
- spermatogenic failure 3 · score 0.06
- spermatogenic failure 55 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6UXY8-F1 | alphafold | PREDICTED | 62.93 | — |
Amino-acid sequence (1006 residues)
MSAYYRNNWS EEDPDYPDYS GSQNRTQGYL KTQGYPDVPG PLNNPDYPGT RSNPYSVASR TRPDYPGSLA EPNYPRSLSN PDYSGTRSNA YSAASRTSPD HPTSLPEPDY SEFQSHPYHR ASSRQPDYPG SQRNPDFAGS SSSGNYAGSR THPDHFGSLE PDYPGAQSNS DHPGPRANLN HPGSRKNLEH TSFRINPYAD SLGKPDYPGA DIQPNSPPFF GEPDYPSAED NQNLPSTWRE PDYSDAENGH DYGSSETPKM TRGVLSRTSS IQPSFRHRSD DPVGSLWGEN DYPEGIEMAS MEMANSYGHS LPGAPGSGYV NPAYVGESGP VHAYGNPPLS ECDWHKSPQG QKLIASLIPM TSRDRIKAIR NQPRTMEEKR NLRKIVDKEK SKQTHRILQL NCCIQCLNSI SRAYRRSKNS LSEILNSISL WQKTLKIIGG KFGTSVLSYF NFLRWLLKFN IFSFILNFSF IIIPQFTVAK KNTLQFTGLE FFTGVGYFRD TVMYYGFYTN STIQHGNSGA SYNMQLAYIF TIGACLTTCF FSLLFSMAKY FRNNFINPHI YSGGITKLIF CWDFTVTHEK AVKLKQKNLS TEIRENLSEL RQENSKLTFN QLLTRFSAYM VAWVVSTGVA IACCAAVYYL AEYNLEFLKT HSNPGAVLLL PFVVSCINLA VPCIYSMFRL VERYEMPRHE VYVLLIRNIF LKISIIGILC YYWLNTVALS GEECWETLIG QDIYRLLLMD FVFSLVNSFL GEFLRRIIGM QLITSLGLQE FDIARNVLEL IYAQTLVWIG IFFCPLLPFI QMIMLFIMFY SKNISLMMNF QPPSKAWRAS QMMTFFIFLL FFPSFTGVLC TLAITIWRLK PSADCGPFRG LPLFIHSIYS WIDTLSTRPG YLWVVWIYRN LIGSVHFFFI LTLIVLIITY LYWQITEGRK IMIRLLHEQI INEGKDKMFL IEKLIKLQDM EKKANPSSLV LERREVEQQG FLHLGEHDGS LDLRSRRSVQ EGNPRA
Explore Transmembrane channel-like protein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets